Severe liver enzyme elevations after three years of olanzapine treatment: A case report and review of olanzapine associated hepatotoxicity

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 6, 2006, Pages 1163-1166

  Ozcanli, Tuba ^a   Erdogan, Ayten ^b   Ozdemir, Samuray ^c   Onen, Bariş ^c   Ozmen, Mine ^c   Doksat, Kerem ^c   Sonsuz, Abdullah ^c  

^a International Hospital Istanbul   (Turkey)

^b Memorial Hospital   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Atypical antipsychotics; Hepatotoxicity; Liver enzymes; Olanzapine; Side effects

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBAMAZEPINE; CHLORPROMAZINE; GAMMA GLUTAMYLTRANSFERASE; HALOPERIDOL; LITHIUM; LIVER ENZYME; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; VALPROIC ACID;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIPOLAR I DISORDER; CASE REPORT; CONVALESCENCE; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INSOMNIA; LARYNX SPASM; LIVER TOXICITY; LONG TERM CARE; MALAISE; NAUSEA; NORMAL VALUE; TREATMENT DURATION; TREMOR;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; FEMALE; HEPATITIS, TOXIC; HUMANS; LIVER; PSYCHIATRIC STATUS RATING SCALES;

EID: 33745474991     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.03.014     Document Type: Article

References (29)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). Fourth Ed. (1994), American Psychiatric Association Publications Division, Washington DC 273-289
2. Ananth J., Venkatesh R., Burgoyne K., Gadasalli R., Binford R., and Gunatilake S. Atypical antipsychotic induced weight gain: pathophysiology and management. Ann Clin Psychiatry 16 (2004) 75-85
3. Ciudad A., Gutiérrez M., Cañas F., Gibert J., Gascón J., Carrasco J., et al. Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study. Prog Neuro-Psychopharmacol Biol Psychiatry 29 6 (2005) 944-951
4. Conley R.R., and Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 158 (2001) 765-774
5. Conley R.R., and Meltzer H.Y. Adverse events related to olanzapine. J Clin Psychiatry 61 Suppl 8 (2000) 26-29
6. Cortez-Pinto H., and Camilo M.E. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol 18 6 (2004) 1089-1104
7. Doucette D.E., Grenier J.P., and Robertson P.S. Olanzapine-induced acute pancreatitis. Ann Pharmacother 34 10 (2000) 1128-1131
8. Dumotier G., Cabaret W., Stamatiais L., Saba G., Benadriha R., Rocamora J.F., et al. Hepatic tolerance of atypical antipsychotic drugs. Encephale 28 (2002) 542-551
9. Erdogan A., Kocabasoglu N., Yalug I., Ozbay G., and Senturk H. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. Int J Psychiatry Med 34 (2004) 83-89
10. Gaertner I., Altendorf K., Batra A., and Gaertner H.J. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7263 treatment courses. J Clin Psychopharmacol 21 (2001) 215-222
11. Garyfallos G., Dimelis D., Kouniakis P., Sidiropoulos N., Karastergiou A., Lavrentiadis G., et al. Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels. Eur Psychiatry 18 (2003) 320-321
12. Gomez J.C., Sacristan J.A., Hernandez J., Breier A., Ruiz Carrasco P., Anton Saiz C., et al. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic study of olanzapine in schizophrenia. J Clin Psychiatry 61 (2000) 335-343
13. Gonzalez-Heydrich J., Raches D., Wilens T.E., Leichtner A., and Mezzacappa E. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex and their combination. J Am Acad Child Adolesc Psychiatry 42 (2003) 1227-1233
14. Haberfellner E.M., and Honsig T. Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics. J Clin Psychiatry 64 (2003) 851
15. Hummer M., Kurz M., Kurtzhaler I., Oberbauer H., Miller C., and Fleischhacker W.W. Hepatotoxicity of clozapine. J Clin Pharmacol 17 (1997) 314-317
16. Jadallah K.A., Limauro D.L., and Colatrella A.M. Acute hepatocellular-cholestatic liver injury after olanzapine therapy. Ann Intern Med 18 138 (2003) 357-358
17. Koller E.A., Cross J.T., Doraiswamy P.M., and Malozowski S.N. Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy 23 9 (2003) 1123-1130
18. Kumra S., Herion D., Jacobsen L.K., Briguglia C., and Grothe D. Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 36 (1997) 1-5
19. Lewis J.H. Drug-induced liver disease. Med Clin North Am 84 (2000) 1275-1311
20. Mouradian-Stamatiadis L., Dumortier G., Januel D., Delmas B.A., and Cabaret W. Liver function tests during treatment with antipsychotic drugs: a case series of 23 patients. Prog Neuro-psychopharmacol Biol Psychiatry 26 (2002) 1409-1411
21. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl. 1 (2005) 1-93
22. Pae C.U., Lim H.K., Kim T.S., Kim J.J., Lee C.U., Lee S.J., et al. Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. Int Clin Psychopharmacol 20 3 (2005) 173-176
23. Raz A., Bergman R., Eilam O., Yungerman T., and Hayek T. A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 321 (2001) 156-158
24. Schwenkreis P., and Assion H.J. Atypical antipsychotics and diabetes mellitus. World J Biol Psychiatry 5 (2004) 73-82
25. Selim K., and Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology 29 (1999) 1347-1351
26. Szigethy E., Wiznitzer M., Branicky L.A., Maxwell K., and Findling R.L. Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol 9 (1999) 93-98
27. Tchernichovsky E., and Sirota P. Hepatotoxicity, leucopenia and neutropenia associated with olanzapine therapy. Int J Psychiatry Clin Pract 8 (2004) 173-177
28. Tollefson G.D., Beasley C.M., Tran Jr. P.V., Street J.S., Krueger J.A., Tamura R.N., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154 (1997) 457-465
29. Waage C., Carlsson H., Nielsen EW. (2004). Olanzapine-induced pancreatitis: a case report. JOP; 10;5(5): 388-391.